Avenue Therapeutics Files 8-K on Financials
Ticker: ATXI · Form: 8-K · Filed: Mar 18, 2024 · CIK: 1644963
Sentiment: neutral
Topics: financial-condition, results-of-operations, filing
Related Tickers: AVTX
TL;DR
AVTX filed an 8-K on 3/18/24 covering financials. Check it out.
AI Summary
On March 18, 2024, Avenue Therapeutics, Inc. filed an 8-K report detailing results of operations and financial condition. The filing includes financial statements and exhibits, with the company's principal executive offices located at 1111 Kane Concourse, Suite 301, Bay Harbor Islands, Florida.
Why It Matters
This filing provides crucial updates on Avenue Therapeutics' financial health and operational performance, which are key factors for investors and stakeholders to assess the company's current standing and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial filing (8-K) and does not appear to contain any new material events or significant negative news.
Key Players & Entities
- Avenue Therapeutics, Inc. (company) — Registrant
- March 18, 2024 (date) — Date of report
- 1111 Kane Concourse, Suite 301, Bay Harbor Islands, Florida 33154 (address) — Principal Executive Offices
- 781-652-4500 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing for Avenue Therapeutics, Inc.?
The primary purpose of this 8-K filing is to report on the Results of Operations and Financial Condition of Avenue Therapeutics, Inc., and it includes Financial Statements and Exhibits.
When was this 8-K report filed?
This 8-K report was filed on March 18, 2024.
Where are Avenue Therapeutics, Inc.'s principal executive offices located?
Avenue Therapeutics, Inc.'s principal executive offices are located at 1111 Kane Concourse, Suite 301, Bay Harbor Islands, Florida 33154.
What is the Commission File Number for Avenue Therapeutics, Inc.?
The Commission File Number for Avenue Therapeutics, Inc. is 001-38114.
What is the IRS Employer Identification Number for Avenue Therapeutics, Inc.?
The IRS Employer Identification Number for Avenue Therapeutics, Inc. is 47-4113275.
Filing Stats: 500 words · 2 min read · ~2 pages · Grade level 11.9 · Accepted 2024-03-18 16:10:23
Filing Documents
- tm248747d1_8k.htm (8-K) — 24KB
- tm248747d1_ex99-1.htm (EX-99.1) — 64KB
- image_002.jpg (GRAPHIC) — 9KB
- 0001104659-24-035544.txt ( ) — 280KB
- atxi-20240318.xsd (EX-101.SCH) — 3KB
- atxi-20240318_lab.xml (EX-101.LAB) — 33KB
- atxi-20240318_pre.xml (EX-101.PRE) — 22KB
- tm248747d1_8k_htm.xml (XML) — 4KB
02
Item 2.02 Results of Operations and Financial Condition. On March 18, 2024, Avenue Therapeutics, Inc. issued a press release to provide a corporate update and to announce its financial results for the fiscal year ended December 31, 2023. A copy of such press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information, including Exhibit 99.1, in this Current Report on Form 8-K is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report on Form 8-K shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall otherwise be expressly set forth by specific reference in such filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits The following exhibits are furnished herewith: Exhibit Number Description 99.1 Press release issued by Avenue Therapeutics, Inc., dated March 18, 2024. 104 Cover Page Interactive Data File (embedded within Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AVENUE THERAPEUTICS, INC. (Registrant) Date: March 18, 2024 By: /s/ David Jin David Jin Interim Principal Financial Officer and Chief Operating Officer